Story file
Are peptides legal? FDA's own lists, peptide by peptide
Are peptides legal? The answer is in FDA documents. We read the category 2 list and the July 2026 advisory agenda and tabled each peptide's status.
It depends on the channel, not the molecule. Approved peptide medicines sit in the approved-drug channel. Pharmacy compounding is governed by FDA’s 503A and 503B bulks process, where many research-market peptides sit in category 2 or on a “nominated but withdrawn” list. A “research use only” label is a use statement, not a legal status.
Are peptides legal? “Peptide” is not a legal category, so this post goes by document. This desk read FDA’s category 2 page, its July 2026 advisory meeting page and its 503A bulks page on 15 October 2026.
Are peptides legal? Three channels, three documents
The first channel, approved drugs, is outside this post.
The second is compounding. FDA’s 503A bulks page says state-licensed physicians and pharmacists compounding under section 503A may only use bulk substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on the 503A bulks list.
The third is the research-use-only vial, a label this desk has assessed as a use statement. Nothing read for this post establishes whether selling or buying such a vial is lawful, so this post makes no claim either way.
What FDA’s category 2 page records, peptide by peptide
FDA’s category 2 page carries two tables. The first lists bulk substances placed in category 2 because they “may present significant safety risks”, with the section (503A, 503B or both) and a date added. The second lists substances “previously in category 2” whose nominations “were withdrawn by the nominators”. That second table has no date column. The page footer reads “Content current as of: 04/22/2026”.
The last column comes from the July 2026 meeting page and, for the votes, from The BMJ’s 28 July report and a client note from Buchanan Ingersoll & Rooney.
| Substance | FDA list, as read 15 Oct 2026 | Section and date added | July 2026 PCAC |
|---|---|---|---|
| GHRP-2 (injectable, nasal) | Category 2 | 503B, 29 Sep 2023 | Not on agenda |
| GHRP-6 | Category 2 | 503B, 29 Sep 2023 | Not on agenda |
| Ipamorelin acetate | Category 2 and withdrawn list | 503B, 29 Sep 2023 | Not on agenda |
| Kisspeptin-10 | Category 2 | 503A, 29 Sep 2023 | Not on agenda |
| Ibutamoren mesylate (not a peptide) | Category 2 | 503A 29 Sep 2023; 503B 29 Dec 2022 | Not on agenda |
| BPC-157 | Withdrawn | No date given | 23 Jul; recommended |
| TB-500 (thymosin beta-4 fragment) | Withdrawn | No date given | 23 Jul; recommended |
| KPV | Withdrawn | No date given | 23 Jul; recommended |
| MOTs-C | Withdrawn | No date given | 23 Jul; recommended |
| Semax | Withdrawn | No date given | 24 Jul; recommended |
| Epitalon | Withdrawn | No date given | 24 Jul; recommended |
| Emideltide (DSIP) | Withdrawn | No date given | 24 Jul; not recommended |
| AOD-9604, CJC-1295, GHK-Cu (injectable), LL-37, dihexa, Melanotan II, PEG-MGF, selank, thymosin-alpha 1 | Withdrawn | No date given | Not on agenda |
Does “withdrawn” mean a peptide is now legal to compound?
No. FDA’s page says only that nominators withdrew the nominations. That is not approval. Healthline’s explainer describes BPC-157 and others as “newly approved for compounding”. The FDA documents read here do not support that wording.
What the July 2026 committee vote is, and is not
FDA’s meeting page lists the seven substances as “being considered for inclusion on the 503A Bulks List”. The same page states that advisory committees make non-binding recommendations, which FDA generally follows but “is not legally bound” to.
The BMJ reported six of the seven passed, each by a narrow majority, with emideltide the exception. Buchanan Ingersoll & Rooney writes that the votes “did not immediately make these peptides lawful for compounding” and that FDA staff had recommended against inclusion. Neither FDA page this desk read on 15 October 2026 records an FDA decision on the votes.
For how this desk reads FDA’s other compounding list, see the 503B Bulks List assessment.
Questions readers ask
Is BPC-157 legal?
For US pharmacy compounding, BPC-157 sits on FDA’s list of substances nominated but withdrawn from category 2, and FDA’s advisory committee discussed it on 23 July 2026 for the 503A Bulks List. The panel recommended it, but that vote is non-binding. Neither FDA page this desk read on 15 October 2026 records FDA placing it on the list.
Is it legal to buy research peptides?
The documents read here do not answer that. FDA’s category 2 page and the advisory process govern which bulk substances pharmacies may compound. They say nothing about selling or buying a vial labelled for laboratory research. A research-use-only label states an intended use; it does not confer a legal status on the material or the sale.
Are peptides legal without a prescription?
The question mixes channels. Compounding under section 503A is done by state-licensed physicians and pharmacists, per FDA’s 503A page. Whether a given peptide can be compounded at all depends on the bulks rules that page sets out. Research-labelled material sits outside that route and outside this desk’s remit for any human use.
Are peptides a controlled substance?
None of the FDA pages this desk read classifies any peptide in the table as a controlled substance. Controlled-substance scheduling is a separate legal question from compounding status, and these compounding documents do not address it. Category 2 is a safety-risk flag for compounding, not a drug schedule.
The ledger line
FDA’s lists are dated documents about pharmacy compounding, not a verdict on any vial. Material discussed on this site is supplied for laboratory research use only, nothing here is medical advice, and no compound in the table is presented as intended for human consumption.